BioCentury
ARTICLE | Politics & Policy

White House pushing Grassley-Wyden drug pricing bill, including inflation caps

November 8, 2019 8:56 PM UTC
Updated on Nov 9, 2019 at 1:58 AM UTC

Enacting drug pricing legislation by the end of December based on the Prescription Drug Pricing Reduction Act (PDPRA) is a top Trump administration priority, Joe Grogan, director of the White House Domestic Policy Council, said Friday at a press briefing. He also signaled that HHS will approve state drug importation plans, and expressed administration support for providing economic incentives to increase adoption of biosimilars.

While White House support is necessary for the enactment of drug pricing legislation, it is not certain that it will be sufficient. PDPRA is facing resistance from Democrats, who favor more dramatic action, and from PhRMA and BIO, which are lobbying against proposals that would attenuate the ability of drug companies to increase prices...